Next 10 |
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting PR Newswire GERMANTOWN, Md. , April 24, 2024 /...
Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Off...
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th PR Newswire – Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP,...
2024-03-22 11:10:58 ET More on Precigen Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript Precigen: RRP Targeting With AdenoVerse Technology Platform Precigen gets EU orphan drug status for respiratory tract drug Seeking Alpha’s Quant Rating on Pr...
2024-03-19 20:49:04 ET Precigen, Inc. (PGEN) Q4 2023 Earnings Conference Call March 19, 2024 04:30 PM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Fina...
2024-03-19 16:09:55 ET More on Precigen Precigen: RRP Targeting With AdenoVerse Technology Platform Precigen gets EU orphan drug status for respiratory tract drug Seeking Alpha’s Quant Rating on Precigen Historical earnings data for Precigen Fi...
Precigen Reports Full Year 2023 Financial Results and Business Updates PR Newswire – Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an accelerated approval pathway in ...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
2024-03-18 17:35:56 ET More on Precigen Precigen: RRP Targeting With AdenoVerse Technology Platform Precigen gets EU orphan drug status for respiratory tract drug Seeking Alpha’s Quant Rating on Precigen Historical earnings data for Precigen Fi...
2024-03-18 17:35:27 ET More on etc. A Bitcoin Strategy Using The 200-Day Simple Moving Average (Technical Analysis) Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Re-Emerging Markets Biggest stock movers today: NVDA, GOOG, FOUR and more ...
News, Short Squeeze, Breakout and More Instantly...
Precigen Inc. Company Name:
PGEN Stock Symbol:
NASDAQ Market:
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting PR Newswire GERMANTOWN, Md. , April 24, 2024 /...
Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Off...
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th PR Newswire – Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP,...